227 related articles for article (PubMed ID: 17629362)
1. Do we fully understand the economic value of vaccines?
Drummond M; Chevat C; Lothgren M
Vaccine; 2007 Aug; 25(32):5945-57. PubMed ID: 17629362
[TBL] [Abstract][Full Text] [Related]
2. Health economic research on vaccinations and immunisation practices--an introductory primer.
Szucs TD
Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
[TBL] [Abstract][Full Text] [Related]
3. [Vaccination: cost-effectiveness ratio].
Swennen B
Rev Med Brux; 2009 Sep; 30(4):451-7. PubMed ID: 19899394
[TBL] [Abstract][Full Text] [Related]
4. [Vaccination--value for money?].
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
[TBL] [Abstract][Full Text] [Related]
5. Emerging issues in vaccine economics: perspectives from the USA.
Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
[TBL] [Abstract][Full Text] [Related]
6. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of thermostable vaccines in Cambodia, Ghana and Bangladesh.
Levin A; Levin C; Kristensen D; Matthias D
Vaccine; 2007 Sep; 25(39-40):6945-57. PubMed ID: 17707556
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
9. Economic evidence of influenza vaccination in children.
Savidan E; Chevat C; Marsh G
Health Policy; 2008 May; 86(2-3):142-52. PubMed ID: 18054109
[TBL] [Abstract][Full Text] [Related]
10. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
Jeuland M; Whittington D
Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
[TBL] [Abstract][Full Text] [Related]
11. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
12. Economics of animal vaccination.
McLeod A; Rushton J
Rev Sci Tech; 2007 Aug; 26(2):313-26. PubMed ID: 17892154
[TBL] [Abstract][Full Text] [Related]
13. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
[TBL] [Abstract][Full Text] [Related]
14. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices.
Salleras L; Navas E; Domínguez A; Ibáñez D; Prat A; Garrido P; Asenjo MA; Torner N
Vaccine; 2009 May; 27(25-26):3454-8. PubMed ID: 19200830
[TBL] [Abstract][Full Text] [Related]
15. The role of health economic analyses in vaccine decision making.
Black S
Vaccine; 2013 Dec; 31(51):6046-9. PubMed ID: 23968768
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of human papillomavirus vaccination in developed countries.
Brisson M; Van de Velde N; Boily MC
Public Health Genomics; 2009; 12(5-6):343-51. PubMed ID: 19684446
[TBL] [Abstract][Full Text] [Related]
17. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis.
Broughton EI
J Public Health (Oxf); 2007 Dec; 29(4):441-8. PubMed ID: 17875589
[TBL] [Abstract][Full Text] [Related]
19. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
[TBL] [Abstract][Full Text] [Related]
20. Methods for risk-benefit and cost-benefit analysis of vaccinations.
Wiedermann G; Ambrosch F
Dev Biol Stand; 1979; 43():429-32. PubMed ID: 118070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
